Atlas Trials

Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer

Clinical trial NCT04345783 · UNKNOWN

Trial details

NCT number
NCT04345783
Sponsor
Beijing Friendship Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric Cancer
Start date
2018-01-01
Primary completion
2021-12-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.